E
Enzalutamide
Availability of ACE Drug Guidance
Yes
Biologics Drug Information Overview
No
Post-marketing information
Dear Healthcare Professional Letters
Subsidy Information and Financing Scheme
Cancer Drug and Clinical Indication listed in the MediShield Life Outpatient Cancer Drug List
Medical Assistance Fund
Active ingredient: Enzalutamide
General information
Subsidy Information and Financing Scheme
[MAF] Enzalutamide Capsule 40 mg
Enzalutamide in combination with androgen deprivation therapy (ADT) for treating patients with high-risk non-metastatic castration-resistant prostate cancer (nmCRPC).
Enzalutamide in combination with androgen deprivation therapy (ADT) for treating patients with metastatic hormone-sensitive prostate cancer (mHSPC).
Enzalutamide in combination with androgen deprivation therapy (ADT) for treating patients with metastatic castration-resistant prostate cancer (mCRPC).
[MSHL] Enzalutamide Capsule 40 mg
Enzalutamide in combination with androgen deprivation therapy (ADT) for treating patients with high-risk non-metastatic castration-resistant prostate cancer (nmCRPC).
Enzalutamide in combination with androgen deprivation therapy (ADT) for treating patients with metastatic castration-resistant prostate cancer (mCRPC).
Enzalutamide in combination with androgen deprivation therapy (ADT) for treating patients with metastatic hormone-sensitive prostate cancer (mHSPC).
Drug Guidance for Subsidy
[NR] The Ministry of Health’s Drug Advisory Committee has not recommended talazoparib in combination with enzalutamide for inclusion on the MOH List of Subsidised Drugs for treating homologous recombination repair gene-mutated metastatic castration-resistant prostate cancer. The decision was based on the low clinical need, uncertain or unfavourable cost-effectiveness compared with treatment alternatives, and the unacceptable price-volume agreement proposed by the company.
Clinical indication, subsidy class and MediShield Life claim limit for talazoparib plus enzalutamide are provided in the Annex.
Post Marketing Information
General Availability in Public Healthcare Institution
Note:
General availability information reflected is based on the Public Healthcare Institutions’ (PHI) formulary on what is commonly used for treating their patient population and may or may not be available for patients not under the care of that institution. It does not reflect the PHI’s actual inventory availability and is subjected to change. Please consult the Public Hospitals or Polyclinics for details on availability and supply restrictions/considerations. General availability is not tied to any brand unless otherwise stated.
Users are to consult the respective PHIs for actual inventory availability and supply restrictions/consideration
Availability information
Formulation | Public Healthcare Institution |
|---|---|
Capsule 40 mg |
|
Registered Product(s) Information
Clinical and product info
Clinical info | Product Info |
|---|---|
Information under the Indication, Dosage and Contraindication sections are extracted from the relevant Package Insert/Patient Information Leaflet of the product available on HSA Infosearch. For more information, please refer to the product's Package Insert/ Patient Information Leaflet available on HSA Infosearch. The information provided is for informational purposes only, and is not exhaustive. The information provided is not a substitute for professional medical advice. Please consult a qualified healthcare provider for any medical advice. | Information available here are product details as registered with the HSA. As this website is updated monthly, please refer to HSA Infosearch for the most updated product information. |
Oral
* Clinical information is available for this product.